A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to posts shared online suggesting the study found signs of an immune ...

How does a COVID-19 mRNA vaccine work? COVID vaccines are now available. Some of the COVID-19 vaccines are mRNA vaccines, but what does this mean? mRNA vaccines are different from traditional ...

Manufacturers facing liability. In an Oct. 21 thread on X, entrepreneur and anti-vaccine activist Steve Kirsch made alarming allegations about mRNA COVID-19 vaccines. “You can now sue the mRNA ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

The investigational mRNA cancer immunotherapy is targeted for patients with lung cancer, melanoma and other solid tumours. Nineteen patients with advanced stage cancers received between one and ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

Moderna (MRNA) concluded the recent trading session at $58.39, signifying a -0.56% move from its prior day's close. Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst ...

New study uncovers a higher prevalence of heart scarring in young males after COVID-19 mRNA vaccination, raising concerns about long-term outcomes despite mild initial symptoms of vaccine ...

Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story.

But this is the first phase-IIb randomised clinical trial to test the investigational mRNA vaccine in patients. Could Covid vaccine technology crack cancer? Patients taking Keytruda for advanced ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. Results from the Phase I trial, also the ...